The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.
about
Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.Targeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutationsThe Biology and Targeting of FLT3 in Pediatric Leukemia.Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220).Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.(Lymph)angiogenic influences on hematopoietic cells in acute myeloid leukemia.Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.Emerging therapeutic drugs for AML.Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.Crotonoside exhibits selective post-inhibition effect in AML cells via inhibition of FLT3 and HDAC3/6.The importance of FLT3 mutational analysis in acute myeloid leukemia.MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
P2860
Q27852520-6E0AD004-BC68-4870-A5F8-4DA3D0A9C3BCQ28539032-95EAD7B0-FF09-42A6-B8FF-8B2A0903B099Q34229555-5E65BDC0-23DD-498F-AFF0-530B0380AE49Q35114397-23B777E3-F87B-484E-8A9D-3FA5234939FFQ35250091-8A7A0C2F-7ABA-47B3-9222-73155D166056Q35750567-CD1C587D-4DCE-48B4-9968-0A76321FA1D9Q36693252-D6894CF4-F724-4A2A-82FE-475678CC0655Q38101284-BF9F6DA5-9F4E-401B-A7BB-3651B1E86465Q38269954-2497B9B2-55DA-4A52-98BE-096F2D9144DDQ38381981-20F049C2-8254-48D9-B07B-98AB6DBABC6FQ38667491-1BACDBD9-56E5-4653-A77C-CD93970CCB87Q39016415-91295ADF-C62F-4B59-9125-E806C31485C0Q40207115-9E911731-4BC3-4C0A-9402-1FC598A3371BQ47104275-ED2E1FA6-57AE-4F72-9567-88C232E50FC8Q48255430-70B8EC58-1661-49F6-83CB-EFDBAA1B8B9DQ48282223-291FAC89-2B14-4554-A21D-F25A2825EEE9
P2860
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
The secondary FLT3-ITD F691L m ...... ivity to PKC412 and Sunitinib.
@en
The secondary FLT3-ITD F691L m ...... ivity to PKC412 and Sunitinib.
@nl
type
label
The secondary FLT3-ITD F691L m ...... ivity to PKC412 and Sunitinib.
@en
The secondary FLT3-ITD F691L m ...... ivity to PKC412 and Sunitinib.
@nl
prefLabel
The secondary FLT3-ITD F691L m ...... ivity to PKC412 and Sunitinib.
@en
The secondary FLT3-ITD F691L m ...... ivity to PKC412 and Sunitinib.
@nl
P2093
P2860
P356
P1433
P1476
The secondary FLT3-ITD F691L m ...... ivity to PKC412 and Sunitinib.
@en
P2093
A L Illert
H Leischner
N von Bubnoff
P2860
P2888
P304
P356
10.1038/LEU.2013.14
P577
2013-01-16T00:00:00Z